Literature DB >> 24131720

The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.

Kathleen McGee1, Hillel Haim, Birgit Korioth-Schmitz, Nicole Espy, Hassan Javanbakht, Norman Letvin, Joseph Sodroski.   

Abstract

Envelope glycoprotein (Env) reactivity (ER) describes the propensity of human immunodeficiency virus type 1 (HIV-1) Env to change conformation from the metastable unliganded state in response to the binding of ligands (antibodies and soluble CD4 [sCD4]) or incubation in the cold. To investigate Env properties that favor in vivo persistence, we inoculated rhesus macaques with three closely related CCR5-tropic simian-human immunodeficiency viruses (SHIVs) that differ in ER to cold (ERcold) and ER to sCD4 (ERsCD4); these SHIVs were neutralized by antibodies equivalently and thus were similar in ERantibody. All three SHIVs achieved high levels of acute viremia in the monkeys without alteration of their Env sequences, indicating that neither ERcold nor ERsCD4 significantly influences the establishment of infection. Between 14 and 100 days following infection, viruses with high ERcold and ERsCD4 were counterselected. Remarkably, the virus variant with low ERcold and low ERsCD4 did not elicit a neutralizing antibody response against the infecting virus, despite the generation of high levels of anti-Env antibodies in the infected monkeys. All viruses that achieved persistent viremia escaped from any autologous neutralizing antibodies and exhibited low ERcold and low ERsCD4. One set of gp120 changes determined the decrease in ERcold and ERsCD4, and a different set of gp120 changes determined resistance to autologous neutralizing antibodies. Each set of changes contributed to a reduction in Env-mediated entry. During infection of monkeys, any Env replication fitness costs associated with decreases in ERcold and ERsCD4 may be offset by minimizing the elicitation of autologous neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131720      PMCID: PMC3911730          DOI: 10.1128/JVI.01558-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  102 in total

Review 1.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.

Authors:  R C Tan; J M Harouse; A Gettie; C Cheng-Mayer
Journal:  J Med Primatol       Date:  1999 Aug-Oct       Impact factor: 0.667

4.  Characterization of primary isolate-like variants of simian-human immunodeficiency virus.

Authors:  J M Crawford; P L Earl; B Moss; K A Reimann; M S Wyand; K H Manson; M Bilska; J T Zhou; C D Pauza; P W Parren; D R Burton; J G Sodroski; N L Letvin; D C Montefiori
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.

Authors:  Z Si; M Cayabyab; J Sodroski
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Authors:  Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Tom Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

10.  Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.

Authors:  Jason A LaBonte; Navid Madani; Joseph Sodroski
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  10 in total

1.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

2.  The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization.

Authors:  Hamid Salimi; Jacklyn Johnson; Manuel G Flores; Michael S Zhang; Yunxia O'Malley; Jon C Houtman; Patrick M Schlievert; Hillel Haim
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

3.  Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.

Authors:  Navid Madani; Amy M Princiotto; Connie Zhao; Fatemeh Jahanbakhshsefidi; Max Mertens; Alon Herschhorn; Bruno Melillo; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

4.  Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.

Authors:  Jacklyn Johnson; Yinjie Zhai; Hamid Salimi; Nicole Espy; Noah Eichelberger; Orlando DeLeon; Yunxia O'Malley; Joel Courter; Amos B Smith; Navid Madani; Joseph Sodroski; Hillel Haim
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.

Authors:  Mohammed Asmal; Corinne Luedemann; Christy L Lavine; Linh V Mach; Harikrishnan Balachandran; Christie Brinkley; Thomas N Denny; Mark G Lewis; Hanne Anderson; Ranajit Pal; Devin Sok; Khoa Le; Matthias Pauthner; Beatrice H Hahn; George M Shaw; Michael S Seaman; Norman L Letvin; Dennis R Burton; Joseph G Sodroski; Barton F Haynes; Sampa Santra
Journal:  Virology       Date:  2014-11-22       Impact factor: 3.616

6.  Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.

Authors:  Hannah M Schapiro; Mukta D Khasnis; Koree Ahn; Alexandra Karagiaridi; Stephanie Hayden; Maria E Cilento; Michael J Root
Journal:  PLoS Pathog       Date:  2022-05-18       Impact factor: 7.464

7.  Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.

Authors:  Hanh T Nguyen; Alessandra Qualizza; Saumya Anang; Meiqing Zhao; Shitao Zou; Rong Zhou; Qian Wang; Shijian Zhang; Ashlesha Deshpande; Haitao Ding; Ta-Jung Chiu; Amos B Smith; John C Kappes; Joseph G Sodroski
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

Review 8.  The Conformational States of the HIV-1 Envelope Glycoproteins.

Authors:  Qian Wang; Andrés Finzi; Joseph Sodroski
Journal:  Trends Microbiol       Date:  2020-05-14       Impact factor: 17.079

9.  An entry-competent intermediate state of the HIV-1 envelope glycoproteins.

Authors:  Alon Herschhorn; Joseph Sodroski
Journal:  Receptors Clin Investig       Date:  2017-05-24

10.  A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.

Authors:  Alon Herschhorn; Christopher Gu; Nicole Espy; Jonathan Richard; Andrés Finzi; Joseph G Sodroski
Journal:  Nat Chem Biol       Date:  2014-08-31       Impact factor: 15.040

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.